Journal
CANCER LETTERS
Volume 287, Issue 2, Pages 216-223Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.06.016
Keywords
Melatonin; Glioma; TRAIL; Apoptosis; Death receptors
Categories
Funding
- ISCIII [FISS-07-PI061803, FIS-08-RD06/0020/1042]
- MCYT [SAF2007-64726]
- Asociacion Espafiola Contra el Cancer (AECC)
- MCYT
- FICYT [BP03-112, COF08-39]
- FISS [FI07/00094]
Ask authors/readers for more resources
Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available